Search research articles
Contact Us
Filters
Showing results (121-130 of 136) with videos related to
Page
of 14
Sort By:
Cancer Chemotherapy and Pharmacology
|
March 5, 2013
A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors
J Capdevila, S Clive, E Casado, et al.
Journal of Neuroendocrinology
|
April 3, 2026
Patterns of response and survival in metastatic paragangliomas and pheochromocytomas: Experience from two Spanish neuroendocrine tumor centers
M I Del Olmo-García, J E Contreras Saldarriaga, L Hernandez-Rienda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2018
Early evolutionary divergence between papillary and anaplastic thyroid cancers
J Capdevila, R Mayor, F M Mancuso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
Early evolutionary divergence between papillary and anaplastic thyroid cancers
J Capdevila, R Mayor, F M Mancuso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2015
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
E Grande, J Capdevila, D Castellano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
M H Kulke, P Ruszniewski, E Van Cutsem, et al.
ESMO Open
|
November 7, 2025
Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors
R Dienstmann, A Vivancos, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
M H Kulke, P Ruszniewski, E Van Cutsem, et al.
ESMO Open
|
July 11, 2022
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)
S Rao, G Anandappa, J Capdevila, et al.
British Journal of Cancer
|
April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours
T A Yap, H Cortes-Funes, H Shaw, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 136) with videos related to
Sort By:
Page
of 14
Cancer Chemotherapy and Pharmacology
|
March 5, 2013
A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumors
J Capdevila, S Clive, E Casado, et al.
Journal of Neuroendocrinology
|
April 3, 2026
Patterns of response and survival in metastatic paragangliomas and pheochromocytomas: Experience from two Spanish neuroendocrine tumor centers
M I Del Olmo-García, J E Contreras Saldarriaga, L Hernandez-Rienda, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 13, 2018
Early evolutionary divergence between papillary and anaplastic thyroid cancers
J Capdevila, R Mayor, F M Mancuso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
Early evolutionary divergence between papillary and anaplastic thyroid cancers
J Capdevila, R Mayor, F M Mancuso, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 12, 2015
Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)
E Grande, J Capdevila, D Castellano, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 23, 2017
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
M H Kulke, P Ruszniewski, E Van Cutsem, et al.
ESMO Open
|
November 7, 2025
Genomic actionability and matched targeted therapy in a decade-long institutional precision medicine program for solid tumors
R Dienstmann, A Vivancos, P Nuciforo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 14, 2019
A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial
M H Kulke, P Ruszniewski, E Van Cutsem, et al.
ESMO Open
|
July 11, 2022
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202)
S Rao, G Anandappa, J Capdevila, et al.
British Journal of Cancer
|
April 12, 2012
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours
T A Yap, H Cortes-Funes, H Shaw, et al.
Page
of 14